Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53

Survivin, a member of the inhibitors-of-apoptosis gene family, is overexpressed in many tumor types. Survivin is a prognostic marker of soft-tissue sarcomas, but the downregulation of survivin expression and the possible dependency of survivin downregulation on p53 in these tumors have not been inve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer gene therapy 2004-03, Vol.11 (3), p.186-193
Hauptverfasser: Kappler, Matthias, Bache, Matthias, Bartel, Frank, Kotzsch, Matthias, Panian, Matti, Würl, Peter, Blümke, Karen, Schmidt, Hannelore, Meye, Axel, Taubert, Helge
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 193
container_issue 3
container_start_page 186
container_title Cancer gene therapy
container_volume 11
creator Kappler, Matthias
Bache, Matthias
Bartel, Frank
Kotzsch, Matthias
Panian, Matti
Würl, Peter
Blümke, Karen
Schmidt, Hannelore
Meye, Axel
Taubert, Helge
description Survivin, a member of the inhibitors-of-apoptosis gene family, is overexpressed in many tumor types. Survivin is a prognostic marker of soft-tissue sarcomas, but the downregulation of survivin expression and the possible dependency of survivin downregulation on p53 in these tumors have not been investigated. Therefore, we applied small interfering RNA (siRNA) to knock down the expression of survivin in five human sarcoma cell lines with wild-type or mutant p53 alleles. Compared with survivin mRNA expression in the nonsense siRNA-treated sarcoma cell lines, expression after treatment with survivin-specific siRNA was reduced by 73–88%; survivin protein expression was reduced by 52–81%. This finding was coupled with a reduction in clonogenic survival ranging from 65–86%. However, less than 10% of cells treated with survivin-specific siRNA underwent apoptosis. Cell-cycle and morphologic analyses showed that after a dramatic increase in the number of treated cells in the G2/M phase, some of the cells became polyploid; this result indicates that mitosis of a substantial number of treated cells was incomplete. Our findings suggest that survivin-specific siRNA could be a selective treatment to kill sarcoma cells regardless of the presence or absence of wild-type p53 alleles.
doi_str_mv 10.1038/sj.cgt.7700677
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_80169887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A182761957</galeid><sourcerecordid>A182761957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c583t-359ceae5efa0aa615f37f6e486ee5f7698230034c9b1dce653bdc2fa992e24713</originalsourceid><addsrcrecordid>eNqFkl1rFDEUhgdR7Fq99VKCQu9mm0wmk-RyKfUDi4LodchmTnazziRjMlPdv-CvNkMHWqVFAgkkz3mSQ96ieEnwmmAqztNhbXbjmnOMG84fFStS86ZkDOPHxQrLSpZEYnpSPEvpgHE-5PRpcZJXKiUVq-L3Rx_M9zb89ChYlKZ47a6dR_BriJCSCx5tjyj1uuuQ8yNEC9H5HfryaYMitJOBhMY9INMFH3bgnVkcupt9-6nXHiUdTeg1MpAtnfO5xvkWBsiTH7vjTA6MPi-eWN0leLGsp8W3t5dfL96XV5_ffbjYXJWGCTqWlEkDGhhYjbVuCLOU2wZq0QAwyxspKooxrY3cktZAw-i2NZXVUlZQ1ZzQ0-LsxjvE8GOCNKrepflt2kOYkhKYZIng_wUJl5IQKTL45h_wEKbocxOqamrCCRZy1r1-kCK8lhVhd1Q73YFy3oYxajPfqzZEVLwhks2q9T1UHi30zgQP1uX9vwrO7hTsQXfjPoVuGvMPp3vNJoaUIlg1RNfreFQEqzlxKh1UTpxaEpcLXi1dTdse2lt8iVgGzm-ANMzRgXjb9gPKP5OX4S8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217492158</pqid></control><display><type>article</type><title>Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kappler, Matthias ; Bache, Matthias ; Bartel, Frank ; Kotzsch, Matthias ; Panian, Matti ; Würl, Peter ; Blümke, Karen ; Schmidt, Hannelore ; Meye, Axel ; Taubert, Helge</creator><creatorcontrib>Kappler, Matthias ; Bache, Matthias ; Bartel, Frank ; Kotzsch, Matthias ; Panian, Matti ; Würl, Peter ; Blümke, Karen ; Schmidt, Hannelore ; Meye, Axel ; Taubert, Helge</creatorcontrib><description>Survivin, a member of the inhibitors-of-apoptosis gene family, is overexpressed in many tumor types. Survivin is a prognostic marker of soft-tissue sarcomas, but the downregulation of survivin expression and the possible dependency of survivin downregulation on p53 in these tumors have not been investigated. Therefore, we applied small interfering RNA (siRNA) to knock down the expression of survivin in five human sarcoma cell lines with wild-type or mutant p53 alleles. Compared with survivin mRNA expression in the nonsense siRNA-treated sarcoma cell lines, expression after treatment with survivin-specific siRNA was reduced by 73–88%; survivin protein expression was reduced by 52–81%. This finding was coupled with a reduction in clonogenic survival ranging from 65–86%. However, less than 10% of cells treated with survivin-specific siRNA underwent apoptosis. Cell-cycle and morphologic analyses showed that after a dramatic increase in the number of treated cells in the G2/M phase, some of the cells became polyploid; this result indicates that mitosis of a substantial number of treated cells was incomplete. Our findings suggest that survivin-specific siRNA could be a selective treatment to kill sarcoma cells regardless of the presence or absence of wild-type p53 alleles.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/sj.cgt.7700677</identifier><identifier>PMID: 14739938</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Alleles ; Apoptosis ; Biomarkers, Tumor ; Biomedical and Life Sciences ; Biomedicine ; Care and treatment ; Cell Line, Tumor ; Cell Survival ; G2 Phase - drug effects ; Gene Expression ; Gene Therapy ; Genetic aspects ; Health aspects ; Humans ; Immunochemistry ; Inhibitor of Apoptosis Proteins ; Methods ; Microtubule-Associated Proteins - antagonists &amp; inhibitors ; Microtubule-Associated Proteins - genetics ; Mitosis ; Neoplasm Proteins ; original-article ; p53 Protein ; Physiological aspects ; Polyploidy ; RNA, Small Interfering - pharmacology ; Sarcoma ; Sarcoma - genetics ; Sarcoma - metabolism ; Sarcoma - therapy ; siRNA ; Survivin ; Tumor cell lines ; Tumor Stem Cell Assay ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism ; Tumors</subject><ispartof>Cancer gene therapy, 2004-03, Vol.11 (3), p.186-193</ispartof><rights>Springer Nature America, Inc. 2004</rights><rights>COPYRIGHT 2004 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Mar 2004</rights><rights>Nature Publishing Group 2004.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c583t-359ceae5efa0aa615f37f6e486ee5f7698230034c9b1dce653bdc2fa992e24713</citedby><cites>FETCH-LOGICAL-c583t-359ceae5efa0aa615f37f6e486ee5f7698230034c9b1dce653bdc2fa992e24713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.cgt.7700677$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.cgt.7700677$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14739938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kappler, Matthias</creatorcontrib><creatorcontrib>Bache, Matthias</creatorcontrib><creatorcontrib>Bartel, Frank</creatorcontrib><creatorcontrib>Kotzsch, Matthias</creatorcontrib><creatorcontrib>Panian, Matti</creatorcontrib><creatorcontrib>Würl, Peter</creatorcontrib><creatorcontrib>Blümke, Karen</creatorcontrib><creatorcontrib>Schmidt, Hannelore</creatorcontrib><creatorcontrib>Meye, Axel</creatorcontrib><creatorcontrib>Taubert, Helge</creatorcontrib><title>Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><addtitle>Cancer Gene Ther</addtitle><description>Survivin, a member of the inhibitors-of-apoptosis gene family, is overexpressed in many tumor types. Survivin is a prognostic marker of soft-tissue sarcomas, but the downregulation of survivin expression and the possible dependency of survivin downregulation on p53 in these tumors have not been investigated. Therefore, we applied small interfering RNA (siRNA) to knock down the expression of survivin in five human sarcoma cell lines with wild-type or mutant p53 alleles. Compared with survivin mRNA expression in the nonsense siRNA-treated sarcoma cell lines, expression after treatment with survivin-specific siRNA was reduced by 73–88%; survivin protein expression was reduced by 52–81%. This finding was coupled with a reduction in clonogenic survival ranging from 65–86%. However, less than 10% of cells treated with survivin-specific siRNA underwent apoptosis. Cell-cycle and morphologic analyses showed that after a dramatic increase in the number of treated cells in the G2/M phase, some of the cells became polyploid; this result indicates that mitosis of a substantial number of treated cells was incomplete. Our findings suggest that survivin-specific siRNA could be a selective treatment to kill sarcoma cells regardless of the presence or absence of wild-type p53 alleles.</description><subject>Alleles</subject><subject>Apoptosis</subject><subject>Biomarkers, Tumor</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Care and treatment</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival</subject><subject>G2 Phase - drug effects</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunochemistry</subject><subject>Inhibitor of Apoptosis Proteins</subject><subject>Methods</subject><subject>Microtubule-Associated Proteins - antagonists &amp; inhibitors</subject><subject>Microtubule-Associated Proteins - genetics</subject><subject>Mitosis</subject><subject>Neoplasm Proteins</subject><subject>original-article</subject><subject>p53 Protein</subject><subject>Physiological aspects</subject><subject>Polyploidy</subject><subject>RNA, Small Interfering - pharmacology</subject><subject>Sarcoma</subject><subject>Sarcoma - genetics</subject><subject>Sarcoma - metabolism</subject><subject>Sarcoma - therapy</subject><subject>siRNA</subject><subject>Survivin</subject><subject>Tumor cell lines</subject><subject>Tumor Stem Cell Assay</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Tumors</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkl1rFDEUhgdR7Fq99VKCQu9mm0wmk-RyKfUDi4LodchmTnazziRjMlPdv-CvNkMHWqVFAgkkz3mSQ96ieEnwmmAqztNhbXbjmnOMG84fFStS86ZkDOPHxQrLSpZEYnpSPEvpgHE-5PRpcZJXKiUVq-L3Rx_M9zb89ChYlKZ47a6dR_BriJCSCx5tjyj1uuuQ8yNEC9H5HfryaYMitJOBhMY9INMFH3bgnVkcupt9-6nXHiUdTeg1MpAtnfO5xvkWBsiTH7vjTA6MPi-eWN0leLGsp8W3t5dfL96XV5_ffbjYXJWGCTqWlEkDGhhYjbVuCLOU2wZq0QAwyxspKooxrY3cktZAw-i2NZXVUlZQ1ZzQ0-LsxjvE8GOCNKrepflt2kOYkhKYZIng_wUJl5IQKTL45h_wEKbocxOqamrCCRZy1r1-kCK8lhVhd1Q73YFy3oYxajPfqzZEVLwhks2q9T1UHi30zgQP1uX9vwrO7hTsQXfjPoVuGvMPp3vNJoaUIlg1RNfreFQEqzlxKh1UTpxaEpcLXi1dTdse2lt8iVgGzm-ANMzRgXjb9gPKP5OX4S8</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>Kappler, Matthias</creator><creator>Bache, Matthias</creator><creator>Bartel, Frank</creator><creator>Kotzsch, Matthias</creator><creator>Panian, Matti</creator><creator>Würl, Peter</creator><creator>Blümke, Karen</creator><creator>Schmidt, Hannelore</creator><creator>Meye, Axel</creator><creator>Taubert, Helge</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7QO</scope><scope>7X8</scope></search><sort><creationdate>20040301</creationdate><title>Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53</title><author>Kappler, Matthias ; Bache, Matthias ; Bartel, Frank ; Kotzsch, Matthias ; Panian, Matti ; Würl, Peter ; Blümke, Karen ; Schmidt, Hannelore ; Meye, Axel ; Taubert, Helge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c583t-359ceae5efa0aa615f37f6e486ee5f7698230034c9b1dce653bdc2fa992e24713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Alleles</topic><topic>Apoptosis</topic><topic>Biomarkers, Tumor</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Care and treatment</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival</topic><topic>G2 Phase - drug effects</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunochemistry</topic><topic>Inhibitor of Apoptosis Proteins</topic><topic>Methods</topic><topic>Microtubule-Associated Proteins - antagonists &amp; inhibitors</topic><topic>Microtubule-Associated Proteins - genetics</topic><topic>Mitosis</topic><topic>Neoplasm Proteins</topic><topic>original-article</topic><topic>p53 Protein</topic><topic>Physiological aspects</topic><topic>Polyploidy</topic><topic>RNA, Small Interfering - pharmacology</topic><topic>Sarcoma</topic><topic>Sarcoma - genetics</topic><topic>Sarcoma - metabolism</topic><topic>Sarcoma - therapy</topic><topic>siRNA</topic><topic>Survivin</topic><topic>Tumor cell lines</topic><topic>Tumor Stem Cell Assay</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kappler, Matthias</creatorcontrib><creatorcontrib>Bache, Matthias</creatorcontrib><creatorcontrib>Bartel, Frank</creatorcontrib><creatorcontrib>Kotzsch, Matthias</creatorcontrib><creatorcontrib>Panian, Matti</creatorcontrib><creatorcontrib>Würl, Peter</creatorcontrib><creatorcontrib>Blümke, Karen</creatorcontrib><creatorcontrib>Schmidt, Hannelore</creatorcontrib><creatorcontrib>Meye, Axel</creatorcontrib><creatorcontrib>Taubert, Helge</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kappler, Matthias</au><au>Bache, Matthias</au><au>Bartel, Frank</au><au>Kotzsch, Matthias</au><au>Panian, Matti</au><au>Würl, Peter</au><au>Blümke, Karen</au><au>Schmidt, Hannelore</au><au>Meye, Axel</au><au>Taubert, Helge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53</atitle><jtitle>Cancer gene therapy</jtitle><stitle>Cancer Gene Ther</stitle><addtitle>Cancer Gene Ther</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>11</volume><issue>3</issue><spage>186</spage><epage>193</epage><pages>186-193</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>Survivin, a member of the inhibitors-of-apoptosis gene family, is overexpressed in many tumor types. Survivin is a prognostic marker of soft-tissue sarcomas, but the downregulation of survivin expression and the possible dependency of survivin downregulation on p53 in these tumors have not been investigated. Therefore, we applied small interfering RNA (siRNA) to knock down the expression of survivin in five human sarcoma cell lines with wild-type or mutant p53 alleles. Compared with survivin mRNA expression in the nonsense siRNA-treated sarcoma cell lines, expression after treatment with survivin-specific siRNA was reduced by 73–88%; survivin protein expression was reduced by 52–81%. This finding was coupled with a reduction in clonogenic survival ranging from 65–86%. However, less than 10% of cells treated with survivin-specific siRNA underwent apoptosis. Cell-cycle and morphologic analyses showed that after a dramatic increase in the number of treated cells in the G2/M phase, some of the cells became polyploid; this result indicates that mitosis of a substantial number of treated cells was incomplete. Our findings suggest that survivin-specific siRNA could be a selective treatment to kill sarcoma cells regardless of the presence or absence of wild-type p53 alleles.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>14739938</pmid><doi>10.1038/sj.cgt.7700677</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0929-1903
ispartof Cancer gene therapy, 2004-03, Vol.11 (3), p.186-193
issn 0929-1903
1476-5500
language eng
recordid cdi_proquest_miscellaneous_80169887
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings
subjects Alleles
Apoptosis
Biomarkers, Tumor
Biomedical and Life Sciences
Biomedicine
Care and treatment
Cell Line, Tumor
Cell Survival
G2 Phase - drug effects
Gene Expression
Gene Therapy
Genetic aspects
Health aspects
Humans
Immunochemistry
Inhibitor of Apoptosis Proteins
Methods
Microtubule-Associated Proteins - antagonists & inhibitors
Microtubule-Associated Proteins - genetics
Mitosis
Neoplasm Proteins
original-article
p53 Protein
Physiological aspects
Polyploidy
RNA, Small Interfering - pharmacology
Sarcoma
Sarcoma - genetics
Sarcoma - metabolism
Sarcoma - therapy
siRNA
Survivin
Tumor cell lines
Tumor Stem Cell Assay
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
Tumors
title Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T13%3A11%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Knockdown%20of%20survivin%20expression%20by%20small%20interfering%20RNA%20reduces%20the%20clonogenic%20survival%20of%20human%20sarcoma%20cell%20lines%20independently%20of%20p53&rft.jtitle=Cancer%20gene%20therapy&rft.au=Kappler,%20Matthias&rft.date=2004-03-01&rft.volume=11&rft.issue=3&rft.spage=186&rft.epage=193&rft.pages=186-193&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/sj.cgt.7700677&rft_dat=%3Cgale_proqu%3EA182761957%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217492158&rft_id=info:pmid/14739938&rft_galeid=A182761957&rfr_iscdi=true